Antoni Chan MD (Prof)
Tweet
Late breaking, ICONIC PsA 1: icotrokinra, a once daily oral peptide targeting the IL23 receptor, in biologic naive PsA. Week 16 ACR20 58% vs 41% with placebo; ACR50 29% vs 16%; clear or almost clear skin 57% vs 14%. Key finding: the primary endpoint was met, with ACR20 69% and
